{"text_format":"5","workbook":"xls","n_sheets":1,"sheets":["report2"],"props":{"last_modified_by":"sharecat"},"not_rendered":{"external_links":1,"defined_names":1},"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[10,2,10,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910778822303321"]
[null,null,"Titolo",null,"Advances in medicine and biology [[electronic resource] ] . Volume 6 / / Leon V. Berhardt, editor"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Biomedical Books, c2010"]
[null,null,"ISBN",null,"1-61728-045-3"]
[null,null,"Descrizione fisica",null,"1 online resource (296 p.)"]
[null,null,"Collana",null,"Advances in Medicine and Biology ; ; v.6"]
[null,null,"Disciplina",null,"616"]
[null,null,"Soggetti",null,"Medicine"]
[{"$nulls":4},"Biology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[{"$nulls":3},"Livello bibliografico","Monografia"]
[{"$nulls":3},"Note generali","Description based upon print version of record."]
[{"$nulls":3},"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"\"\"ADVANCES IN MEDICINE AND BIOLOGY VOLUME 6\"\"; \"\"CONTENTS\"\"; \"\"PREFACE\"\"; \"\"ZINC-BASED BIOMATERIALS\"\"; \"\"BIOLOGICAL ASPECTS OF ZINC\"\"; \"\"ZINC BIOMATERIALS\"\"; \"\"ZINC OXYCHLORIDE CEMENTS\"\"; \"\"ZINC OXIDE EUGENOL CEMENTS\"\"; \"\"ZINC PHOSPHATE CEMENTS\"\"; \"\"ZINC POLYCARBOXYLATE CEMENTS\"\"; \"\"GLASS POLY(ALKENOATE) CEMENTS\"\"; \"\"GLASSES USED IN GPCS\"\"; \"\"ACID COMPONENTS USED IN GPCS\"\"; \"\"THE ROLE OF ADDITIVES TO GPCS\"\"; \"\"MECHANICAL PROPERTIES OF GPCS\"\"; \"\"BIOLOGICAL AND ION RELEASE PROPERTIES OF GPCS\"\"; \"\"ALUMINIUM FREE GPCS\"\"; \"\"STRUCTURE AND REACTIVITY OF ALUMINIUM FREE IONOMERGLASSES\"\""]
[{"$nulls":4},"\"\"STRENGTH OF ALUMINIUM-FREE GPCS\"\"\"\"OPTIMISATION OF RHEOLOGICAL PROPERTIES OF ZN-GPCS\"\"; \"\"IN VITRO ANALYSIS OF ALUMINIUM-FREE GPCS\"\"; \"\"IN VIVO ANALYSIS OF ALUMINIUM-FREE GPCS\"\"; \"\"OTHER ASPECTS OF ALUMINIUM-FREE GPCS\"\"; \"\"APPLICATIONS FOR ALUMINIUM-FREE GPCS\"\"; \"\"FUTURE PERSPECTIVES OF ALUMINIUM-FREE GPCS\"\"; \"\"REFERENCES\"\"; \"\"THE EFFECTS OF DRUGS ON VERBAL FLUENCY:MECHANISMS OF DRUG RELATED FLUENCY INAPHASIA\"\"; \"\"ABSTRACT\"\"; \"\"INTRODUCTION\"\"; \"\"NEUROANATOMY OF SPEECH AND LANGUAGE\"\"; \"\"NEUROCHEMICAL BASES OF SPEECH AND LANGUAGE\"\"; \"\"The Primary Neurotransmitters\"\""]
[{"$nulls":4},"\"\"Glutamate, Î³-Aminobutyric Acid and Glycine\"\"\"\"Neuromodulators and Hormones\"\"; \"\"Catecholamines\"\"; \"\"Acetylcholine\"\"; \"\"Serotonin\"\"; \"\"DEFINITION OF FLUENCY\"\"; \"\"NEUROPHARMACOLOGY OF VERBAL FLUENCY, SPEECH ANDLANGUAGE\"\"; \"\"Agents which Increase Cerebral Perfusion\"\"; \"\"Dopaminergic Agents\"\"; \"\"Amphetamines\"\"; \"\"Serotonin\"\"; \"\"Cholinergic Drugs\"\"; \"\"Piracetam\"\"; \"\"Zolpidem\"\"; \"\"Amantadine\"\"; "]
[{"$nulls":4},"\"\"Antiepileptic Agents\"\"; \"\"Drugs which have Speech and Language Side Effects\"\"; \"\"CLINICAL CASE\"\"; \"\"CONCLUSION\"\"; \"\"REFERENCES\"\"; \"\"PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE\"\"; \"\"ABSTRACT\"\""]
[{"$nulls":4},"\"\"1. CLINICAL FEATURES OF PSORIASIS\"\"\"\"2. TREATMENT OPTIONS FOR PSORIASIS\"\"; \"\"3. PATHOGENESIS OF PSORIASIS\"\"; \"\"4. SYSTEMIC MANIFESTATIONS OF INFLAMMATORYDISORDERS\"\"; \"\"5. CLINICAL LINK BETWEEN PSORIASIS ANDATHEROSCLEROSIS\"\"; \"\"6. OPHTHALMIC AND RENAL MANIFESTATIONS OFPSORIASIS\"\"; \"\"7. SIMILARITIES BETWEEN MOLECULAR MECHANISMS OFPSORIASIS AND OTHER INFLAMMATORY DISORDERS\"\"; \"\"8. CAN TREATMENT OF PSORIASIS ALSO IMPROVE ITSSYSTEMIC MANIFESTATION?\"\"; \"\"9. DELINEATING PSORIASIS AS A MULTISYSTEMINFLAMMATORY DISEASE: \"\"5 YEAR VIEW\"\"\"\"; \"\"REFERENCES\"\""]
[{"$nulls":4},"\"\"REPACKAGING OF ANTI-GLAUCOMAMEDICINES:NEW THERAPEUTIC VISTAS\"\"\"\"ABSTRACT\"\"; \"\"INTRODUCTION\"\"; \"\"CHOLINERGIC AGENTS\"\"; \"\"Pilocarpine\"\"; \"\"NON-SELECTIVE ADRENERGIC AGONISTS\"\"; \"\"CARBONIC ANHYDRASE INHIBITORS\"\"; \"\"Acetazolamide\"\"; \"\"Dorzolamide and Brinzolamide\"\"; \"\"Î±2-ADRENERGIC AGONIST\"\"; \"\"BETA-BLOCKING AGENTS\"\"; \"\"Timolol\"\"; \"\"Betaxolol\"\"; \"\"Levobunolol\"\"; \"\"Carteolol\"\"; \"\"PROSTAGLANDIN ANALOGS\"\"; \"\"Unoprostone Isopropylate\"\"; \"\"Latanoprost\"\"; \"\"COMBIMATION\"\"; \"\"CONCLUSION\"\"; \"\"REFERENCES\"\"; \"\"THE UTILIZATION OF TECHNOLOGY IN THETREATMENT OF OBSESSIVE COMPULSIVEDISORDER\"\"; \"\"ABSTRACT\"\""]
[{"$nulls":4},"\"\"INTRODUCTION\"\""]